## Management of DIC in APL **Key Point:** All-trans retinoic acid (ATRA) is the drug of choice for acute promyelocytic leukemia (APL) and is uniquely effective in resolving DIC associated with this malignancy. ### Mechanism in APL-DIC 1. **ATRA mechanism:** Induces differentiation of abnormal promyelocytes into mature neutrophils, reducing the release of procoagulant substances (tissue factor, cancer procoagulant) from leukemic cells. 2. **DIC resolution:** As leukemic burden decreases and cells differentiate, the trigger for DIC (release of thromboplastic substances) is eliminated. 3. **Rapid effect:** ATRA produces clinical improvement in coagulopathy within days to weeks. ### Why ATRA is Superior | Feature | ATRA | Chemotherapy Alone | |---------|------|-------------------| | **Mechanism** | Differentiation therapy | Cytotoxic (worsens DIC initially) | | **DIC course** | Improves rapidly | May worsen before improving | | **Leukostasis risk** | Lower | Higher with chemotherapy | | **Induction remission rate** | ~90% when combined with chemotherapy | Lower as monotherapy | **High-Yield:** ATRA + arsenic trioxide (ATO) is now the preferred induction regimen in many centers, with superior outcomes and lower toxicity compared to ATRA + chemotherapy. **Clinical Pearl:** In APL-DIC, supportive care (FFP, cryoprecipitate, platelets, low-dose heparin if indicated) is given concurrently with ATRA to manage coagulopathy while the underlying disease is treated. ### Differentiation Syndrome (ATRA Toxicity) ATRA can cause differentiation syndrome (formerly "retinoic acid syndrome") — fever, respiratory distress, weight gain, pulmonary infiltrates — managed with dexamethasone.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.